Hallux patch during anti-transcription intermediary factor-1γ dermatomyositis

被引：0
|
作者：
Kluger, Nicolas [1 ,2 ]
机构：
[1] Univ Helsinki, Dept Dermatol Allergol & Venereol, Helsinki, Finland
[2] Helsinki Univ Hosp, Helsinki, Finland
来源：
CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 10期
关键词：
ANTIBODIES;
D O I：
10.1093/ced/llae142
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This case illustrates that the hallux patch sign, among others, is not restricted to anti-MDA5 dermatomyositis.
引用
收藏
页码：1246 / 1247
页数：2
相关论文
共 50 条
  • [1] Anti-transcription intermediary factor-1γ/α/β antibody-positive dermatomyositis associated with multiple panniculitis lesions
    Yanaba, Koichi
    Tanito, Katsumi
    Hamaguchi, Yasuhito
    Nakagawa, Hidemi
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (11) : 1831 - 1834
  • [2] Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis
    Zhang, Suo
    Chen, Yu-Lan
    Liu, Cui-Lian
    Xie, Jing-Yi
    Sun, Bao-Dong
    Liu, Dong-Zhou
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody
    Mizumaki, Kie
    Makino, Satoshi
    Ikawa, Yuka
    Maeda, Shintaro
    Horii, Motoki
    Fushida, Natsumi
    Hamaguchi, Yasuhito
    Nohara, Takahiro
    Izumi, Koji
    Matsushita, Takashi
    JOURNAL OF DERMATOLOGY, 2022, 49 (09): : E311 - E312
  • [4] Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
    Kurushima, Shota
    Horai, Yoshiro
    Umeda, Masataka
    Kawakami, Atsushi
    INTERNAL MEDICINE, 2017, 56 (21) : 2965 - 2966
  • [5] Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients
    Ogawa-Momohara, M.
    Muro, Y.
    Mitsuma, T.
    Katayama, M.
    Yanaba, K.
    Nara, M.
    Kakeda, M.
    Kono, M.
    Akiyama, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : 990 - 995
  • [6] Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore
    Chua, Choon Guan
    Low, Jia Zhen
    Manghani, Mona
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [7] A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody"
    Koizumi, Haruka
    Muro, Yoshinao
    Imai, Satoko
    Yamashita, Yuta
    Ogawa-Momohara, Mariko
    Takeichi, Takuya
    Murakami, Megumi
    Mitsuma, Teruyuki
    Akiyama, Masashi
    JOURNAL OF DERMATOLOGY, 2023, 50 (01): : E39 - E40
  • [8] Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis
    Venalis, Paulius
    Selickaja, Sandra
    Lundberg, Karin
    Rugiene, Rita
    Lundberg, Ingrid E.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (04) : 648 - 651
  • [9] Association of serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis
    Li, Xi
    Bai, Jingjing
    Li, Siting
    Li, Mengtao
    Zeng, Xiaofeng
    Wang, Qian
    Hu, Chaojun
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 230 - 237
  • [10] Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis
    Wu, Wanlong
    Chen, Jinju
    Zhu, Linling
    Sha, Yaping
    Wang, Kaiwen
    Zhao, Jiangfeng
    Ye, Chunhua
    Ye, Shuang
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 285 - 287
12345